Anke E. Kip

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Road to FAIR genomes: a gap analysis of NGS data generation and sharing in the Netherlands.

Road to FAIR genomes: a gap analysis of NGS data generation and sharing in the Netherlands.

Journal: BMJ open science

Published: December 06, 2021

Blood Parasite Load as an Early Marker to Predict Treatment Response in Visceral Leishmaniasis in Eastern Africa.

Blood Parasite Load as an Early Marker to Predict Treatment Response in Visceral Leishmaniasis in Eastern Africa.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: November 09, 2020

Low antileishmanial drug exposure in HIV-positive visceral leishmaniasis patients on antiretrovirals: an Ethiopian cohort study.

Low antileishmanial drug exposure in HIV-positive visceral leishmaniasis patients on antiretrovirals: an Ethiopian cohort study.

Journal: The Journal of antimicrobial chemotherapy

Published: August 28, 2020

Characterizing the non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients from Eastern Africa.

Characterizing the non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients from Eastern Africa.

Journal: The Journal of antimicrobial chemotherapy

Published: September 25, 2019

Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration.

Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration.

Journal: BMJ open

Published: September 11, 2019

Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial.

Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: March 23, 2018

Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis.

Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis.

Journal: Frontiers in cellular and infection microbiology

Published: February 27, 2018

Simultaneous population pharmacokinetic modelling of plasma and intracellular PBMC miltefosine concentrations in New World cutaneous leishmaniasis and exploration of exposure-response relationships.

Simultaneous population pharmacokinetic modelling of plasma and intracellular PBMC miltefosine concentrations in New World cutaneous leishmaniasis and exploration of exposure-response relationships.

Journal: The Journal of antimicrobial chemotherapy

Published: August 26, 2017

Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs.

Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs.

Journal: Clinical pharmacokinetics

Published: July 31, 2017

Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study.

Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study.

Journal: The Journal of antimicrobial chemotherapy

Published: March 16, 2017

Pharmacokinetics of Miltefosine in Children and Adults with Cutaneous Leishmaniasis.

Pharmacokinetics of Miltefosine in Children and Adults with Cutaneous Leishmaniasis.

Journal: Antimicrobial agents and chemotherapy

Published: October 14, 2016

Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial.

Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial.

Journal: PLoS neglected tropical diseases

Published: February 22, 2016

Showing 1-12 of 14

Last Updated: 09/26/2026